Protein Degradation Using PROTACs and Molecular Glues Icon

Cambridge Healthtech Institute’s 5th Annual

Protein Degradation Using PROTACs & Molecular Glues

April 19-20, 2022


The ubiquitin-proteasome, lysosome and autophagy systems are all well-controlled, selective pathways for intracellular protein degradation and turnover, and act as key regulators in cancer, CNS and other diseases. A new generation of inhibitors and activators are now being developed to modulate these pathways, disrupt protein-protein interactions and hijack these systems for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other small molecule-based modalities are being used to seek out previously “undruggable” protein targets for drug discovery and therapeutic applications. However, challenges do exist in terms of specificity, stability, biodistribution and penetration of these degrader molecules. The conference on Protein Degradation Using PROTACs & Molecular Glues brings together experts in the field to discuss important issues underlying the use of targeted protein degradation as a new approach for therapeutic intervention.


Coverage will likely include:


  • Use of PROTACs and molecular glues for degrading various drug targets
  • Update on development of new degrader modalities
  • Design, characterization and optimization of protein degraders
  • Finding new ligases and deubiquitinases (DUBs) for modulating undruggable targets
  • Understanding challenges around degrader specificity and adverse events
  • Tackling issues surrounding stability, biodistribution, tissue penetration and more


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is October 1, 2021.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


We hope you can join us for this and the 4 concurrent day-and-a-half conferences during the first half of our 17th Annual Drug Discovery Chemistry event. Registering for this conference lets you also move back and forth among parallel programs to create your own agenda, whether you join in person or virtually.


For more details on the conference, please contact:

Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute



For partnering and sponsorship information, please contact:

Aimee Croke
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5458